Safety and Efficacy of CD10367 in Psoriasis Vulgaris

NCT03025282 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
24
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Galderma R&D